CD19 targeted CAR T Cell Therapy for Diffuse Large B-Cell Lymphoma

Phase-Based Progress Estimates
Diffuse Large B-Cell Lymphoma+4 MoreCD19 targeted CAR T Cell Therapy - Biological
All Sexes
What conditions do you have?

Study Summary

This trial will test whether receiving the pneumococcal 13-valent conjugate vaccine before and after CD19-targeted CAR T cell therapy will help to create immunity against pneumococcus.

Eligible Conditions
  • Diffuse Large B-Cell Lymphoma
  • Primary Mediastinal Large B-Cell Lymphoma
  • Diffuse Large B-Cell Lymphoma (DLBCL)
  • Transformed Follicular Lymphoma
  • Follicular Lymphoma

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 5 Secondary · Reporting Duration: at 90 days and 180 days post CAR T therapy

Day 180
Overall Survival
Day 90
Humoral Response Rate -PCV13 vaccine
Increase in On-Specific Serotype IgG levels
Response Rate of CD19-targeted CAR T therapy when combined with PCV13 vaccination
Day 180
Progression Free Survival

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

1 Treatment Group

1 of 1

Experimental Treatment

26 Total Participants · 1 Treatment Group

Primary Treatment: CD19 targeted CAR T Cell Therapy · No Placebo Group · Phase 2

TreatmentExperimental Group · 2 Interventions: Pneumococcal conjugate vaccine (PCV13), CD19 targeted CAR T Cell Therapy · Intervention Types: Biological, Biological

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: at 90 days and 180 days post car t therapy

Who is running the clinical trial?

H. Lee Moffitt Cancer Center and Research InstituteLead Sponsor
503 Previous Clinical Trials
125,963 Total Patients Enrolled
Frederick Locke, MDPrincipal InvestigatorMoffitt Cancer Center

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are willing to comply with all study procedures and are available for the duration of the study.